Loading
A phase 2 trial of pembrolizumab and olaparib in pancreatic cancer, run by Cambridge University Hospitals NHS Foundation Trust, now recruiting.
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT05093231 by Cambridge University Hospitals NHS Foundation Trust, with a registry enrolment figure of 20 participants, started 2025-02-26 and due to reach its primary completion in 2027-07-31. Interventions recorded: Pembrolizumab; Olaparib. Conditions listed: Pancreatic Cancer. Primary outcome: Objective Response Rate (ORR). Sites: Australia, United Kingdom. United Kingdom sites listed: 15. No results are recorded here; the registry entry is the source.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares PARP inhibitors, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares PARP inhibitors, Olaparib, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.